CDI Labs

In a recent paper published in Frontiers in Immunology, Dr. Ying Ye and colleagues at the Chongqing Medical University revealed down-regulated autoantibodies in early lung cancer patients. These tumor-associated autoantibodies can be detected months to years before diagnosis, offering a promising avenue for earlier detection. Using large-scale screening with , researchers identified 15 decreased autoantibodies that provide 80% sensitivity and 87% specificity for stage IA lung cancer. Notably, 10 of these autoantibodies returned to normal levels post-surgery, indicating their potential as biomarkers for residual tumors.

Read blog here,
https://www.cdilabs.com/blogs/down-regulated-autoantibodies-in-early-lung-cancer-patients

View / download paper here,
https://www.cdilabs.com/content/publications/pub-exploration-of-the-diagnostic-and-prognostic-roles-ye

View paper in Frontiers in Immunology,
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1538071/full

In this insightful blog by Shaohui Hu, Wendy Yap and Shuang Liu, we explore the history and innovation of ™, the world’s largest, most comprehensive protein microarray. Representing over 81% of the human proteome, HuProt revolutionizes the study of protein functions and interactions with the broadest coverage and accuracy. Developed by Heng Zhu’s team at Johns Hopkins University in 2009, HuProt builds on decades of advancements in proteomics and enables breakthroughs in biomarker discovery, disease research, and drug development. Furthermore, HuProt is complemented by cutting-edge technologies like ® PhIP-Seq for epitope analysis and ® for antibody profiling. See how CDI Labs is driving proteomics innovation forward.

View blog here,
https://www.cdilabs.com/blogs/unlocking-the-secrets-of-the-human-proteome

Unlock the secrets of the human immune system with ® PHIP-Seq, the cutting-edge platform revolutionizing pathogen detection and immune profiling. Powered by Phage Display ImmunoPrecipitation Sequencing (PHIP-Seq), VirScan takes immune analysis to the next level. By uncovering antibodies generated across an individual's unique history of viral exposures, it provides unparalleled insights into how the immune system has responded to past and present infections.

From decoding the intricate interplay of immunity to transforming disease research and diagnostics, VirScan® PHIP-Seq enables researchers to:

✔ Map an Individual's Viral Exposure
✔ Reveal Immune System Dynamics in Unprecedented Detail
✔ Drive Next-Gen Discoveries in Medicine and Health

Learn more,
https://cdilabs.ca/services/virscan-phip-seq